AOD-9604 + CJC-1295 + IPA Blend 12mg-6mg-6mg

Research Peptide for Metabolic Support, Recovery & Cellular Regeneration

The AOD-9604 CJC-1295 Ipamorelin peptide blend is a research formulation designed to combine three distinct yet complementary mechanisms: targeted fat metabolism, growth hormone (GH) secretion, and cellular repair. This synergy makes it a valuable compound for researchers studying metabolic regulation, tissue recovery, and body composition.

Each component of the blend contributes unique properties:

• AOD-9604 (12 mg) – a fragment of human growth hormone (HGH 176–191) known for its lipolytic action.
• CJC-1295 (6 mg) – a growth-hormone–releasing hormone (GHRH) analog that promotes steady GH secretion.
• Ipamorelin (6 mg) – a selective GH secretagogue that enhances pituitary GH release without affecting other hormones.

Together, these peptides form a multi-pathway model for studying fat metabolism, energy balance, and tissue regeneration.

Understanding the AOD-9604 CJC-1295 Ipamorelin Peptide Blend

This blend merges a fat-metabolism peptide with two GH secretagogues to create a comprehensive research tool. The combination targets both peripheral and central metabolic pathways, simulating coordinated effects observed in natural hormonal rhythms.

Key Mechanistic Targets

• AOD-9604: Stimulates β-adrenergic lipolysis while inhibiting lipogenesis, aiding fat oxidation.
• CJC-1295: Prolongs GH release by binding to serum albumin, extending the peptide’s half-life.
• Ipamorelin: Triggers GH pulses selectively through the ghrelin receptor pathway, minimizing cortisol or prolactin elevation.

By combining these mechanisms, the AOD-9604 CJC-1295 Ipamorelin peptide blend provides a more complete picture of metabolic signaling and recovery dynamics.

Research-Observed Benefits

Investigators have explored this peptide combination in several areas of metabolic and endocrine science:

• Fat-Metabolism Support – AOD-9604 enhances lipolysis and inhibits fat formation.
• Increased Growth Hormone Output – CJC-1295 and Ipamorelin stimulate GH secretion through complementary pathways.
• Improved Body Composition – Synergistic activity may promote fat reduction while preserving lean mass in laboratory models.
• Cellular Repair and Recovery – GH elevation supports protein synthesis and tissue regeneration.
• Restful Sleep and Circadian Balance – Studies link GH pulse optimization with improved recovery cycles.
• Joint and Cartilage Health – Secondary GH-mediated pathways may aid connective-tissue maintenance.

These outcomes make the AOD-9604 CJC-1295 Ipamorelin peptide blend a popular target for metabolic and longevity research.

Mechanism of Action

The blend operates through a dual-axis mechanism:

1. Peripheral Metabolism – AOD-9604 activates lipolytic enzymes to enhance fatty-acid oxidation.
2. Central Endocrine Signaling – CJC-1295 and Ipamorelin stimulate pituitary GH release, raising circulating GH and IGF-1 levels within physiologic parameters.

In research models, this combination has been linked to improved mitochondrial efficiency, greater substrate utilization, and enhanced recovery following stress or exertion.

For scientific references, see PubMed Research on AOD-9604 and CJC-1295 + Ipamorelin Studies.

Why Choose GRAM Peptides

• Pharmacist-Formulated Quality – Developed by a licensed compounding pharmacist with over two decades of experience.
• USA Manufacturing – Produced in ISO-compliant facilities using validated protocols.
• Third-Party Testing – Each batch verified for purity, identity, and potency.
• Transparent Documentation – COA and technical data available for all research lots.

GRAM Peptides delivers consistency and reliability for professional researchers requiring accurate peptide formulations.

Research Applications

The AOD-9604 CJC-1295 Ipamorelin peptide blend is being explored in:

• Obesity and Metabolic Studies – Fat oxidation, adipose regulation, and energy expenditure.
• Endocrine Research – Growth-hormone release patterns and feedback control.
• Regenerative Medicine Models – Tissue healing, collagen synthesis, and recovery kinetics.
• Sports Science – GH-mediated repair and muscle preservation without anabolic signaling.
• Combination Peptide Therapies – Paired with Tirzepatide or L-Carnitine to evaluate synergistic metabolic effects.

Frequently Asked Questions

What is the AOD-9604 CJC-1295 Ipamorelin peptide blend?
A research-grade formulation combining three peptides studied for their roles in fat metabolism, GH secretion, and tissue repair.

Is this blend FDA-approved?
No. It is for Research Use Only (RUO) and not for human or veterinary administration.

What are the strengths available?
Each vial contains AOD-9604 12 mg + CJC-1295 6 mg + Ipamorelin 6 mg, lyophilized for stability.

Does this blend affect IGF-1 levels?
Research indicates that GH release via CJC-1295 and Ipamorelin can raise IGF-1 modestly without supraphysiologic spikes.

Can this compound be used in multi-peptide protocol research?
Yes. It is frequently studied alongside metabolic and recovery peptides for comparative data.

Related Peptides for Metabolic Research

• AOD-9604 Peptide – Studied for fat oxidation and energy metabolism.
• Tirzepatide Peptide – Dual GIP/GLP-1 agonist researched for metabolic balance.
• L-Carnitine – Explored for fat transport and mitochondrial function.

Disclaimer

The AOD-9604 CJC-1295 Ipamorelin peptide blend is sold strictly for Research Use Only (RUO). Not for human consumption, medical, or veterinary use.